Improvement of outcome prediction of hospitalized patients with COVID-19 by a dual marker strategy using high-sensitive cardiac troponin I and copeptin

COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kaufmann, Christoph C. (VerfasserIn) , Ahmed, Amro (VerfasserIn) , Kassem, Mona (VerfasserIn) , Freynhofer, Matthias K. (VerfasserIn) , Jäger, Bernhard (VerfasserIn) , Aicher, Gabriele (VerfasserIn) , Equiluz-Bruck, Susanne (VerfasserIn) , Spiel, Alexander O. (VerfasserIn) , Vafai-Tabrizi, Florian (VerfasserIn) , Gschwantler, Michael (VerfasserIn) , Fasching, Peter (VerfasserIn) , Wojta, Johann (VerfasserIn) , Giannitsis, Evangelos (VerfasserIn) , Huber, Kurt (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2022
In: Clinical research in cardiology
Year: 2022, Jahrgang: 111, Heft: 3, Pages: 343-354
ISSN:1861-0692
DOI:10.1007/s00392-021-01970-4
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00392-021-01970-4
Volltext
Verfasserangaben:Christoph C. Kaufmann, Amro Ahmed, Mona Kassem, Matthias K. Freynhofer, Bernhard Jäger, Gabriele Aicher, Susanne Equiluz-Bruck, Alexander O. Spiel, Florian Vafai-Tabrizi, Michael Gschwantler, Peter Fasching, Johann Wojta, Evangelos Giannitsis, Kurt Huber
Beschreibung
Zusammenfassung:COVID-19 has been associated with a high prevalence of myocardial injury and increased cardiovascular morbidity. Copeptin, a marker of vasopressin release, has been previously established as a risk marker in both infectious and cardiovascular disease.
Beschreibung:Published online: 15 November 2021
Gesehen am 13.04.2022
Beschreibung:Online Resource
ISSN:1861-0692
DOI:10.1007/s00392-021-01970-4